Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

被引：0
|
作者：
Charles E. Geyer
Hanna Bandos
Priya Rastogi
Samuel A. Jacobs
André Robidoux
Louis Fehrenbacher
Patrick J. Ward
Jonathan Polikoff
Adam M. Brufsky
Louise Provencher
Alexander H. G. Paterson
John T. Hamm
Robert L. Carolla
Luis Baez-Diaz
Thomas B. Julian
Sandra M. Swain
Eleftherios P. Mamounas
Norman Wolmark
机构：
[1] NRG Oncology,Department of Biostatistics
[2] UPMC Hillman Cancer Center,Department of Oncology
[3] University of Pittsburgh,Department of Surgery, Breast Cancer Research Group (GRCS)
[4] Magee Womens Hospital,Department of Medical Oncology
[5] Centre Hospitalier de l’Université de Montréal (CHUM),Department of Research and Evaluation – Clinical Trials
[6] Kaiser Permenente Northern California,Oncology
[7] Onoclogy/Hematology Care Clinical Trials,Department of Oncology
[8] Kaiser Permanente Southern California,Department of Medical Oncology, CCOP
[9] Centre des Maladies du Sein du CHU de Québec – Université Laval,Cancer Medicine Department of Hematology/Oncology
[10] Tom Baker Cancer Centre,Department of Surgery
[11] Norton Cancer Institute,Department of Research Development, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
[12] Ozark Health Ventures LLC-Cancer Research for the Ozarks,Department of Surgery
[13] Puerto Rico NCORP/UPR Comprehensive Cancer Center,undefined
[14] Allegheny Health Network/Allegheny General Hospital,undefined
[15] MedStar Health,undefined
[16] Orlando Health UF Health Cancer Center,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 193卷
关键词：
Node-negative breast cancer; Anthracyclines; Duration of therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：555 / 564
页数：9
相关论文
共 49 条
  • [11] NSABP B-47: A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
    Fehrenbacher, L.
    Jeong, J-H
    Rastogi, P.
    Geyer, C. E.
    Paik, S.
    Ganz, P. A.
    Land, S. R.
    Costantino, J. P.
    Swain, S. M.
    Mamounas, E. P.
    Wolmark, N.
    [J]. CANCER RESEARCH, 2011, 71
  • [12] A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast Cancer Patients (Trial B2000)
    Delbaldo, C.
    Serin, D.
    Mousseau, M.
    Greget, S.
    Audhuy, B.
    Priou, F.
    Berdah, J-F
    Teissier, E.
    Quinaux, E.
    Piedbois, P.
    [J]. CANCER RESEARCH, 2010, 70
  • [13] NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer
    Fehrenbacher, Louis
    Jeong, Jong-Hyeon
    Rastogi, Priya
    Geyer, Charles E.
    Paik, Soonmyung
    Ganz, Patricia A.
    Land, Stephanie R.
    Costantino, Joseph P.
    Swain, Sandra M.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [14] Prerandomization surgical training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial - A randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer
    Harlow, SP
    Krag, DN
    Julian, TB
    Ashikaga, T
    Weaver, DL
    Feldman, SA
    Klimberg, VS
    Kusminsky, R
    Moffat, FL
    Noyes, RD
    Beitsch, PD
    [J]. ANNALS OF SURGERY, 2005, 241 (01) : 48 - 54
  • [15] A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer:: Final results
    Rouëssé, J
    De la Lande, B
    Bertheault-Cvitkovic, F
    Serin, D
    Graïc, Y
    Combe, M
    Leduc, B
    Lucas, V
    Demange, L
    Nguyen, TD
    Castèra, D
    Krzisch, C
    Villet, R
    Mouret-Fourme, E
    Garbay, JR
    Noguès, C
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (04): : 1072 - 1080
  • [16] NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
    Fehrenbacher, Louis
    Cecchini, Reena S.
    Geyer, Charles E., Jr.
    Rastogi, Priya
    Costantino, Joseph P.
    Atkins, James N.
    Crown, John P.
    Polikoff, Jonathan
    Boileau, Jean-Francois
    Provencher, Louise
    Stokoe, Christopher
    Moore, Timothy D.
    Robidoux, Andre
    Flynn, Patrick J.
    Borges, Virginia F.
    Albain, Kathy S.
    Swain, Sandra M.
    Paik, Soonmyung
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05) : 444 - 453
  • [17] NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E.
    Rastogi, Priya
    Atkins, James Norman
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan
    Brufsky, Adam
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Perez, Edith A.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [18] Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
    Krag, David N.
    Anderson, Stewart J.
    Bjulian, Thomas
    Brown, Ann M.
    Harlow, Seth P.
    Ashikaga, Takamaru
    Weaver, Donald L.
    Miller, Barbara J.
    Jalovec, Lynne M.
    Frazier, Thomas G.
    Noyes, R. Dirk
    Robidoux, Andre
    Scarth, Hugh M. C.
    Mammolito, Denise M.
    McCready, David R.
    Mamounas, Eleftherios P.
    Costantino, Joseph P.
    Wolmark, Norman
    [J]. LANCET ONCOLOGY, 2007, 8 (10): : 881 - 888
  • [19] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
    Inhwan Hwang
    Jeong Eun Kim
    Jae Ho Jeong
    Jin-Hee Ahn
    Kyung Hae Jung
    Byung Ho Son
    Hak Hee Kim
    Junyoung Shin
    Hee Jin Lee
    Gyungyub Gong
    Sung-Bae Kim
    [J]. Breast Cancer Research and Treatment, 2023, 201 : 193 - 204
  • [20] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
    Hwang, Inhwan
    Kim, Jeong Eun
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Son, Byung Ho
    Kim, Hak Hee
    Shin, Junyoung
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Sung-Bae
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 193 - 204
12345